Single photon emission computed tomography imaging for temporal dynamics of thyroidal and salivary radionuclide accumulation in 17-allyamino-17- demothoxygeldanamycin-treated thyroid cancer mouse model

Endocrine-Related Cancer

Volumn 18, Issue 1, 2011, Pages 27-37

  Liu, Yu Yu ^a   Brandt, Michael P ^a   Shen, Daniel H ^b   Kloos, Richard T ^a   Zhang, Xiaoli ^a   Jhiang, Sissy M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYAMINO 17 DEMOTHOXYGELDANAMYCIN; GELDANAMYCIN; LIOTHYRONINE; PROTEIN PATCHED 1; PROTEIN RET; RADIOACTIVE IODINE; THYROGLOBULIN; THYROTROPIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; SALIVARY GLAND; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID GLAND; THYROID TUMOR; WILD TYPE;

ANIMALS; BENZOQUINONES; DISEASE MODELS, ANIMAL; HSP90 HEAT-SHOCK PROTEINS; IMAGING, THREE-DIMENSIONAL; LACTAMS, MACROCYCLIC; MICE; RECEPTORS, CELL SURFACE; SALIVARY GLANDS; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79251470132     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-10-0185     Document Type: Article

References (34)

1. Burniat A, Jin L, Detours V, Driessens N, Goffard JC, Santoro M, Rothstein J, Dumont JE, Miot F & Corvilain B 2008 Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers. Endocrinology 149 5107-5117. (doi:10.1210/en.2008-0531)
2. - symporter distribution in human thyroid tissues: an immunohistochemical study. Journal of Clinical Endocrinology and Metabolism 83 4102-4106. (doi:10.1210/jc.83.11.4102)
3. Cantraine FR & Dewandre B 1975 Kinetics of the thyroid follicle lumen diffusion subsystem: application to iodide accumulation by the thyroid follicle in vitro. Bulletin of Mathematical Biology 37 301-321. (doi:10.1007/BF02461448)
4. Castro MR, Bergert ER, Goellner JR, Hay ID & Morris JC 2001 Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. Journal of Clinical Endocrinology and Metabolism 86 5627-5632. (doi:10.1210/jc.86.11.5627)
5. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A & Papini E 2009 Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. European Journal of Endocrinology/European Federation of Endocrine Societies 160 431-436. (doi:10.1530/EJE-08-0669)
6. Cho JY, Sagartz JE, Capen CC, Mazzaferri EL & Jhiang SM 1999 Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice. Oncogene 18 3659-3665. (doi:10.1038/sj.onc.1202709)
7. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M et al. 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19 1167-1214. (doi:10.1089/thy.2009.0110)
8. Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F, Traino C, Pacini F & Pinchera A 2006 Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. Journal of Clinical Endocrinology and Metabolism 91 2389-2395. (doi:10.1210/jc.2005-2480)
9. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L et al. 2009 Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism 94 4171-4179. (doi:10.1210/jc.2009-0869)
10. Franken PR, Guglielmi J, Vanhove C, Koulibaly M, Defrise M, Darcourt J & Pourcher T 2010 Distribution and dynamics of (99m)Tc-pertechnetate uptake in the thyroid and other organs assessed by single-photon emission computed tomography in living mice. Thyroid 20 519-526. (doi:10.1089/thy.2009.0213)
11. Garcia B & Santisteban P 2002 PI3K is involved in the IGF-1 inhibition of TSH-induced sodium/iodide symporter gene expression. Molecular Endocrinology 16 342-352. (doi:10.1210/me.16.2.342)
12. Guyot H, Sulon J, Beckers J-F, Closset J, Lebreton P, de Oliveira LA & Rollin F 2007 Development and validation of a radioimmunoassay for thyrotropin in cattle. Journal of Veterinary Diagnostic Investigation 19 643-651.
13. Holm S 1979 A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6 65-70.
14. Hou P, Bojdani E & Xing M 2010 Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. Journal of Clinical Endocrinology and Metabolism 95 820-828. (doi:10.1210/jc.2009-1888)
15. - symporter mRNA expression in rat FRTL-5 cells. Endocrine Journal 51 415-423. (doi:10.1507/endocrj.51.415)
16. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, Xing S & Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137 375-378. (doi:10.1210/en.137.1. 375)
17. - symporter and iodine accumulation on poorly differentiated thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism 86 3430-3435. (doi:10.1210/jc.86.7.3430)
18. Kloos RT 2009 Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid 19 925-928. (doi:10.1089/thy.2009.0236)
19. Knauf JA, Kuroda H, Basu S & Fagin JA 2003 RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22 4406-4412. (doi:10.1038/sj.onc.1206602)
20. Knostman KA, Jhiang SM & Capen CC 2007 Genetic alterations in thyroid cancer: the role of mouse models. Veterinary Pathology 44 1-14. (doi:10.1354/vp.44-1-1)
21. Kogai T, Sajid-Crockett S, Newmarch LS, Liu YY&Brent GA 2008 Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells. Journal of Endocrinology 199 243-252. (doi:10.1677/JOE-08-0333)
22. Luster M, Clarke SE, Ditelein M, Lassman M, Lind P, Oyen WJG, Tennvall J & Bombardieri E 2008 Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 35 1941-1959. (doi:10.1007/s00259-008-0883-1)
23. Marsee DK, Venkateswaran A, Tao H, Vadysirisack D, Zhang Z, Vandre DD & Jhiang SM 2004 Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. Journal of Biological Chemistry 279 43990-43997. (doi:10.1074/jbc. M407503200)
24. Oler G & Cerutti JM 2009 High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 115 972-980. (doi:10.1002/cncr.24118)
25. de Oliveira E, Teixeira Silva Fagundes A, Teixeira Bonomo I, Curty FH, Fonseca Passos MC, de Moura EG&Lisboa PC 2007 Acute and chronic leptin effect upon in vivo and in vitro rat thyroid iodide uptake. Life Sciences 81 1241-1246. (doi:10.1016/j.lfs.2007.08.030)
26. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E et al. 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology and Metabolism 91 926-932. (doi:10.1210/jc.2005-1651)
27. Patel A, Jhiang S, Dogra S, Terrell R, Powers PA, Fenton C, Dinauer CA, Tuttle RM & Francis GL 2002 Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents. Pediatric Research 52 737-744.
28. Pötzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C & Dudczak R 2006 Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clinical Endocrinology 65 519-523. (doi:10.1111/j.1365-2265.2006.02626.x)
29. Shen DH, Kloos RT, Mazzaferri EL & Jhiang SM 2001 Sodium iodide symporter in health and disease. Thyroid 11 415-425. (doi:10.1089/ 105072501300176372)
30. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G & Larson S 2010 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 20 257-263. (doi:10.1089/thy.2009. 0401)
31. Vadysirisack DD, Venkateswaran A, Zhang Z & Jhiang SM 2007 MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner. Endocrine-Related Cancer 14 421-432. (doi:10.1677/erc.1. 01263)
32. Ward LS, Santarosa PL, Granja F, da Assumpção LV, Savoldi M & Goldman GH 2003 Low expression of sodium iodide symporter identifies aggressive thyroid tumors. Cancer Letters 200 85-91. (doi:10.1016/S0304-3835(03) 00392-6)
33. Zaballos MA, Garcia B & Santisteban P 2008 Gbg dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells. Molecular Endocrinology 22 1183-1199. (doi:10.1210/me.2007-0093)
34. Zuckier LS, Dohan O, Li Y, Chang CJ, Carrasco N & Dadachova E 2004 Kinetics of perrhenate uptake and comparative biodistribution of perrhenate, pertechnetate, and iodide by NaI symporter-expressing tissues in vivo. Journal of Nuclear Medicine 45 500-507.